Pub Date : 2026-01-23DOI: 10.1016/S0147-0272(26)00007-3
{"title":"Information for Readers","authors":"","doi":"10.1016/S0147-0272(26)00007-3","DOIUrl":"10.1016/S0147-0272(26)00007-3","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"60 ","pages":"Article 101273"},"PeriodicalIF":2.3,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-21DOI: 10.1016/j.currproblcancer.2026.101268
Sm Faysal Bellah , S M Saker Billah
Background
The CYP3A5 gene plays a crucial role in drug metabolism and carcinogen activation, potentially influencing breast cancer susceptibility. However, its genetic association with breast cancer risk in the Bangladeshi population remains under explored.
Objective
This study aims to examine the expression and genetic correlation of the CYP3A5*3 (rs776746) polymorphism in relation to breast cancer susceptibility.
Methods
A case-control study was performed with 150 breast cancer patients and 150 healthy controls to investigate genotypic variations of the CYP3A5*3 (rs776746) polymorphism using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis. The relationship between the CYP3A5*3 variant and breast cancer risk was assessed by calculating odds ratios (ORs) and 95% confidence intervals (CIs) through logistic regression models.
Results
The CYP3A5*3 polymorphism exhibited a significant association with increased breast cancer risks. Breast cancer risk was found to be higher in heterozygotes than in homozygotes. Individuals carrying the heterozygous (*1/*3) and mutant homozygote (*3/*3) genotypes had a 3.04-fold (p = 0.0005) and 1.9-fold (p = 0.0227) increased risk of developing breast cancer respectively. Furthermore, the combined (*1/*3 + *3/*3) genotype was significantly linked to a 3.67-fold higher susceptibility to breast cancer risks (p < 0.0005).
Conclusion
Our findings suggest that the CYP3A5*3 polymorphism is significantly associated with an elevated risk of breast cancer in Bangladeshi population.
{"title":"Title: Impact of CYP3A5*3 genetic polymorphism on breast cancer risk: Evidence from Bangladesh","authors":"Sm Faysal Bellah , S M Saker Billah","doi":"10.1016/j.currproblcancer.2026.101268","DOIUrl":"10.1016/j.currproblcancer.2026.101268","url":null,"abstract":"<div><h3>Background</h3><div>The <em>CYP3A5</em> gene plays a crucial role in drug metabolism and carcinogen activation, potentially influencing breast cancer susceptibility. However, its genetic association with breast cancer risk in the Bangladeshi population remains under explored.</div></div><div><h3>Objective</h3><div>This study aims to examine the expression and genetic correlation of the <em>CYP3A5<strong>*</strong>3</em> (rs776746) polymorphism in relation to breast cancer susceptibility.</div></div><div><h3>Methods</h3><div>A case-control study was performed with 150 breast cancer patients and 150 healthy controls to investigate genotypic variations of the <em>CYP3A5*3</em> (rs776746) polymorphism using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis. The relationship between the <em>CYP3A5*3</em> variant and breast cancer risk was assessed by calculating odds ratios (ORs) and 95% confidence intervals (CIs) through logistic regression models.</div></div><div><h3>Results</h3><div>The <em>CYP3A5<strong>*</strong>3</em> polymorphism exhibited a significant association with increased breast cancer risks. Breast cancer risk was found to be higher in heterozygotes than in homozygotes. Individuals carrying the heterozygous (*1/*3) and mutant homozygote (*3/*3) genotypes had a 3.04-fold (<em>p</em> = 0.0005) and 1.9-fold (<em>p</em> = 0.0227) increased risk of developing breast cancer respectively. Furthermore, the combined (*1/*3 + *3/*3) genotype was significantly linked to a 3.67-fold higher susceptibility to breast cancer risks (<em>p</em> < 0.0005).</div></div><div><h3>Conclusion</h3><div>Our findings suggest that the <em>CYP3A5<strong>*</strong>3</em> polymorphism is significantly associated with an elevated risk of breast cancer in Bangladeshi population.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"61 ","pages":"Article 101268"},"PeriodicalIF":2.3,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146020893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-20DOI: 10.1016/j.currproblcancer.2026.101269
Shivani Vaja , Shubhi Khandelwal , Chaitali Vora , Abdul Arif Khan , Syed Wajeed , M. Hassan Sk , Mirza S. Baig
Chimeric Antigen Receptor T (CAR-T) cell therapy, in combination with other treatments or medications, presents a groundbreaking development in cancer immunotherapy. CAR-T immunotherapy has shown remarkable progress, with multiple therapies approved by the US FDA for hematological malignancies. Studies indicate that CAR-NK and CAR-M therapies are more effective against solid tumors than CAR-T-based therapy. The synergistic potential of combining CAR-based therapies with immunomodulatory agents, cytokines, oncolytic viruses, and immune checkpoint inhibitors presents a promising strategy for treating various cancers. This comprehensive review examines the current status and application of CAR-T, CAR-NK, and CAR-M therapies, particularly their integration with immunomodulatory agents and other molecules for treating solid tumors, including glioblastoma, pancreatic, gastric, liver, ovarian, lung, and breast cancers.
{"title":"CAR-T/NK/M-based combination therapies in cancer: A comprehensive review","authors":"Shivani Vaja , Shubhi Khandelwal , Chaitali Vora , Abdul Arif Khan , Syed Wajeed , M. Hassan Sk , Mirza S. Baig","doi":"10.1016/j.currproblcancer.2026.101269","DOIUrl":"10.1016/j.currproblcancer.2026.101269","url":null,"abstract":"<div><div>Chimeric Antigen Receptor T (CAR-T) cell therapy, in combination with other treatments or medications, presents a groundbreaking development in cancer immunotherapy. CAR-T immunotherapy has shown remarkable progress, with multiple therapies approved by the US FDA for hematological malignancies. Studies indicate that CAR-NK and CAR-M therapies are more effective against solid tumors than CAR-T-based therapy. The synergistic potential of combining CAR-based therapies with immunomodulatory agents, cytokines, oncolytic viruses, and immune checkpoint inhibitors presents a promising strategy for treating various cancers. This comprehensive review examines the current status and application of CAR-T, CAR-NK, and CAR-M therapies, particularly their integration with immunomodulatory agents and other molecules for treating solid tumors, including glioblastoma, pancreatic, gastric, liver, ovarian, lung, and breast cancers.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"61 ","pages":"Article 101269"},"PeriodicalIF":2.3,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146020847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1016/j.currproblcancer.2026.101267
Isha Shah , Diksha Dev Yadav , Brig. Dr Anil Khetrapal , Giriraj Saini , Pankaj Malhotra , Lalit Kumar
{"title":"Successful autologous stem cell transplantation in a case of multiple myeloma with mechanical heart valves","authors":"Isha Shah , Diksha Dev Yadav , Brig. Dr Anil Khetrapal , Giriraj Saini , Pankaj Malhotra , Lalit Kumar","doi":"10.1016/j.currproblcancer.2026.101267","DOIUrl":"10.1016/j.currproblcancer.2026.101267","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"61 ","pages":"Article 101267"},"PeriodicalIF":2.3,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145957777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The present study investigated the clinical impact of electronic patient-reported outcome (ePRO) monitoring on chemotherapy dose intensities and adverse event (AE) management in patients with early-stage breast cancer receiving neoadjuvant chemotherapy.
Methods
In this single-center retrospective study, conducted between October 2022 and June 2024, we compared outcomes between patients treated with and without ePRO monitoring during neoadjuvant chemotherapy. The primary endpoint was the percentage of patients who achieved an average relative dose intensity (ARDI) of ≥85 %. The secondary endpoint was the persistence of grade ≥2 non-hematologic AEs, defined as symptoms that remained unresolved (i.e., not improved to grade ≤1) by the start of the subsequent chemotherapy cycle. Follow-ups continued until October 31, 2024.
Results
Ninety-six patients were analyzed (ePRO group, n = 42; usual care group, n = 54). The percentage of patients achieving ARDI ≥85 % was significantly higher in the ePRO group than in the usual care group (85.7 % vs. 66.7 %, p = 0.029). The persistence of non-hematologic AEs was significantly lower in the ePRO group (p = 0.002). A multivariate analysis confirmed that ePRO use was independently associated with ARDI ≥85 % (odds ratio [OR], 4.05; 95 % confidence interval [CI], 1.04–15.8; p = 0.045) and reduced AE persistence (OR, 0.08; 95 % CI, 0.01–0.49; p = 0.002).
Conclusion
ePRO monitoring may help to maintain chemotherapy dose intensities and shorten the duration of AEs in early-stage breast cancer patients receiving neoadjuvant chemotherapy.
目的：本研究探讨电子患者报告预后（ePRO）监测对早期乳腺癌新辅助化疗患者化疗剂量强度和不良事件（AE）处理的临床影响。方法：在这项于2022年10月至2024年6月进行的单中心回顾性研究中，我们比较了在新辅助化疗期间接受和未接受ePRO监测的患者的结果。主要终点是达到平均相对剂量强度(ARDI)≥85%的患者百分比。次要终点是持续≥2级非血液学ae，定义为在随后的化疗周期开始时症状仍未解决（即未改善到≤1级）。随访一直持续到2024年10月31日。结果：共分析96例患者，其中ePRO组42例，常规护理组54例。ePRO组达到ARDI≥85%的患者比例显著高于常规护理组（85.7% vs. 66.7%, p = 0.029）。ePRO组非血液学ae的持续时间显著降低（p = 0.002）。多因素分析证实，ePRO的使用与ARDI≥85%（优势比[OR]， 4.05； 95%可信区间[CI]， 1.04-15.8; p = 0.045）和AE持续性降低独立相关（OR, 0.08; 95% CI, 0.01-0.49; p = 0.002）。结论：ePRO监测有助于早期乳腺癌新辅助化疗患者维持化疗剂量强度，缩短ae持续时间。
{"title":"Electronic symptom monitoring improves chemotherapy dose intensity in neoadjuvant chemotherapy for breast cancer","authors":"Yuki Takei , Atsufumi Nomoto , Mizuki Kawashima , Yuko Miyake , Arisa Kawakami , Tadamitsu Shima , Isao Teshima , Natsumi Nomoto , Yoshiharu Mitsunaga , Tamaki Watanabe , Yukie Nagase , Nobuhiro Yasuno","doi":"10.1016/j.currproblcancer.2025.101266","DOIUrl":"10.1016/j.currproblcancer.2025.101266","url":null,"abstract":"<div><h3>Purpose</h3><div>The present study investigated the clinical impact of electronic patient-reported outcome (ePRO) monitoring on chemotherapy dose intensities and adverse event (AE) management in patients with early-stage breast cancer receiving neoadjuvant chemotherapy.</div></div><div><h3>Methods</h3><div>In this single-center retrospective study, conducted between October 2022 and June 2024, we compared outcomes between patients treated with and without ePRO monitoring during neoadjuvant chemotherapy. The primary endpoint was the percentage of patients who achieved an average relative dose intensity (ARDI) of ≥85 %. The secondary endpoint was the persistence of grade ≥2 non-hematologic AEs, defined as symptoms that remained unresolved (i.e., not improved to grade ≤1) by the start of the subsequent chemotherapy cycle. Follow-ups continued until October 31, 2024.</div></div><div><h3>Results</h3><div>Ninety-six patients were analyzed (ePRO group, <em>n</em> = 42; usual care group, <em>n</em> = 54). The percentage of patients achieving ARDI ≥85 % was significantly higher in the ePRO group than in the usual care group (85.7 % vs. 66.7 %, <em>p</em> = 0.029). The persistence of non-hematologic AEs was significantly lower in the ePRO group (<em>p</em> = 0.002). A multivariate analysis confirmed that ePRO use was independently associated with ARDI ≥85 % (odds ratio [OR], 4.05; 95 % confidence interval [CI], 1.04–15.8; <em>p</em> = 0.045) and reduced AE persistence (OR, 0.08; 95 % CI, 0.01–0.49; <em>p</em> = 0.002).</div></div><div><h3>Conclusion</h3><div>ePRO monitoring may help to maintain chemotherapy dose intensities and shorten the duration of AEs in early-stage breast cancer patients receiving neoadjuvant chemotherapy.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"60 ","pages":"Article 101266"},"PeriodicalIF":2.3,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145776591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-05DOI: 10.1016/j.currproblcancer.2025.101264
Anmar Ghanim Taki , Abdulkareem Shareef , Vimal Arora , Rami Oweis , S. Renuka Jyothi , Udaybir Singh , Samir Sahoo , Ashish Singh Chauhan , Farzona Alimova , Hayder Naji Sameer , Ahmed Yaseen , Zainab H. Athab , Mohaned Adil
The human microbiome, encompassing microbial communities in the gut and breast tissue, has emerged as a critical modulator of breast cancer (BC) initiation, progression, and treatment response. This review synthesizes current evidence on the microbiome’s role in BC, highlighting its influence on tumorigenesis, tumor microenvironment (TME), and therapeutic outcomes. Breast cancer, the most prevalent malignancy among women globally, exhibits significant heterogeneity across its molecular subtype’s hormone receptor-positive, HER2-enriched, and triple-negative—each with distinct clinical challenges. Recent studies reveal that microbial dysbiosis in the gut and breast tissue can drive oncogenesis through mechanisms such as immune modulation, estrogen metabolism, and inflammation. Gut microbes, via the “estrobolome,” regulate circulating estrogen levels, impacting hormone-driven BC, while breast tissue microbiota contributes to local inflammation and DNA damage, promoting tumor progression. Specific microbial taxa, including Bacillus, Staphylococcus, and Escherichia coli, are enriched in BC patients, whereas beneficial species like Lactobacillus and Bifidobacterium are diminished. The microbiome also influences treatment efficacy, with gut microbial diversity linked to enhanced chemotherapy and immunotherapy responses, while antibiotic-induced dysbiosis may impair outcomes. Emerging research suggests microbiome signatures as potential biomarkers for predicting therapeutic success, with Akkermansia muciniphila and short-chain fatty acids showing promise in enhancing anti-tumor immunity. Probiotics, prebiotics, and fecal microbiota transplantation offerel therapeutic avenues, though challenges such as standardization, interindividual variability, and safety concerns remain. Integrating multi-omics and machine learning could elucidate microbiome-host interactions, paving the way for precision oncology. This review underscores the transformative potential of microbiome-based diagnostics and interventions in improving BC management, emphasizing the need for large-scale, longitudinal studies to validate these findings and address existing research gaps.
{"title":"Unraveling the microbiome’s role in breast cancer progression and treatment response","authors":"Anmar Ghanim Taki , Abdulkareem Shareef , Vimal Arora , Rami Oweis , S. Renuka Jyothi , Udaybir Singh , Samir Sahoo , Ashish Singh Chauhan , Farzona Alimova , Hayder Naji Sameer , Ahmed Yaseen , Zainab H. Athab , Mohaned Adil","doi":"10.1016/j.currproblcancer.2025.101264","DOIUrl":"10.1016/j.currproblcancer.2025.101264","url":null,"abstract":"<div><div>The human microbiome, encompassing microbial communities in the gut and breast tissue, has emerged as a critical modulator of breast cancer (BC) initiation, progression, and treatment response. This review synthesizes current evidence on the microbiome’s role in BC, highlighting its influence on tumorigenesis, tumor microenvironment (TME), and therapeutic outcomes. Breast cancer, the most prevalent malignancy among women globally, exhibits significant heterogeneity across its molecular subtype’s hormone receptor-positive, HER2-enriched, and triple-negative—each with distinct clinical challenges. Recent studies reveal that microbial dysbiosis in the gut and breast tissue can drive oncogenesis through mechanisms such as immune modulation, estrogen metabolism, and inflammation. Gut microbes, via the “estrobolome,” regulate circulating estrogen levels, impacting hormone-driven BC, while breast tissue microbiota contributes to local inflammation and DNA damage, promoting tumor progression. Specific microbial taxa, including Bacillus, Staphylococcus, and Escherichia coli, are enriched in BC patients, whereas beneficial species like Lactobacillus and Bifidobacterium are diminished. The microbiome also influences treatment efficacy, with gut microbial diversity linked to enhanced chemotherapy and immunotherapy responses, while antibiotic-induced dysbiosis may impair outcomes. Emerging research suggests microbiome signatures as potential biomarkers for predicting therapeutic success, with Akkermansia muciniphila and short-chain fatty acids showing promise in enhancing anti-tumor immunity. Probiotics, prebiotics, and fecal microbiota transplantation offerel therapeutic avenues, though challenges such as standardization, interindividual variability, and safety concerns remain. Integrating multi-omics and machine learning could elucidate microbiome-host interactions, paving the way for precision oncology. This review underscores the transformative potential of microbiome-based diagnostics and interventions in improving BC management, emphasizing the need for large-scale, longitudinal studies to validate these findings and address existing research gaps.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"60 ","pages":"Article 101264"},"PeriodicalIF":2.3,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145694886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-24DOI: 10.1016/j.currproblcancer.2025.101265
Jingru Han, Simeng Gao, Man Li, Xiao Li
This meta-analysis evaluated the efficacy and safety of combining immune checkpoint inhibitors (ICIs) with chemotherapy in triple-negative breast cancer (TNBC). We systematically searched PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) comparing immunotherapy plus chemotherapy with chemotherapy alone in TNBC patients, published from inception through 30 June 2022. Outcomes included pathological complete response (pCR), progression-free survival (PFS), overall survival (OS), adverse events (AEs), and immune-related AEs (irAEs), analyzed using hazard ratios (HRs) or odds ratios (ORs). The addition of ICIs to chemotherapy improved pCR (OR 1.90, 95 % CI: 1.28-2.83, *P* = 0.002) and event-free survival (EFS) (HR 0.65, 95 % CI: 0.51-0.82, *P* = 0.0004) in the neoadjuvant setting. Notably, pCR benefits persisted regardless of PD-L1 status (OR 1.65, 95 % CI: 1.26-2.16, *P* = 0.0002 in PD-L1-positive patients; OR 1.56, 95 % CI: 1.04-2.33, *P* = 0.03 in PD-L1-negative patients). In the adjuvant setting, ICIs significantly prolonged PFS in both the intention-to-treat population (HR 0.82, 95 % CI: 0.74-0.90, *P* < 0.0001, *I*² = 0 %) and PD-L1-positive subgroups (HR 0.71, 95 % CI: 0.62-0.82, *P* < 0.00001, *I*² = 12 %). However, combination therapy increased the incidence of any-grade AEs, serious AEs, and grade ≥3 AEs in neoadjuvant treatment. The experimental group also exhibited higher toxicity for irAEs, including hypothyroidism and hyperthyroidism. These findings support the use of ICIs with chemotherapy for TNBC, though careful monitoring of adverse effects is warranted. PROSPERO registration number:CRD42022367366.
{"title":"Efficacy and safety of immunotherapy combined with chemotherapy in both neoadjuvant and adjuvant settings among triple-negative breast cancer: A meta-analysis of randomized clinical trials.","authors":"Jingru Han, Simeng Gao, Man Li, Xiao Li","doi":"10.1016/j.currproblcancer.2025.101265","DOIUrl":"https://doi.org/10.1016/j.currproblcancer.2025.101265","url":null,"abstract":"<p><p>This meta-analysis evaluated the efficacy and safety of combining immune checkpoint inhibitors (ICIs) with chemotherapy in triple-negative breast cancer (TNBC). We systematically searched PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) comparing immunotherapy plus chemotherapy with chemotherapy alone in TNBC patients, published from inception through 30 June 2022. Outcomes included pathological complete response (pCR), progression-free survival (PFS), overall survival (OS), adverse events (AEs), and immune-related AEs (irAEs), analyzed using hazard ratios (HRs) or odds ratios (ORs). The addition of ICIs to chemotherapy improved pCR (OR 1.90, 95 % CI: 1.28-2.83, *P* = 0.002) and event-free survival (EFS) (HR 0.65, 95 % CI: 0.51-0.82, *P* = 0.0004) in the neoadjuvant setting. Notably, pCR benefits persisted regardless of PD-L1 status (OR 1.65, 95 % CI: 1.26-2.16, *P* = 0.0002 in PD-L1-positive patients; OR 1.56, 95 % CI: 1.04-2.33, *P* = 0.03 in PD-L1-negative patients). In the adjuvant setting, ICIs significantly prolonged PFS in both the intention-to-treat population (HR 0.82, 95 % CI: 0.74-0.90, *P* < 0.0001, *I*² = 0 %) and PD-L1-positive subgroups (HR 0.71, 95 % CI: 0.62-0.82, *P* < 0.00001, *I*² = 12 %). However, combination therapy increased the incidence of any-grade AEs, serious AEs, and grade ≥3 AEs in neoadjuvant treatment. The experimental group also exhibited higher toxicity for irAEs, including hypothyroidism and hyperthyroidism. These findings support the use of ICIs with chemotherapy for TNBC, though careful monitoring of adverse effects is warranted. PROSPERO registration number:CRD42022367366.</p>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":" ","pages":"101265"},"PeriodicalIF":2.3,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-17DOI: 10.1016/S0147-0272(25)00086-8
{"title":"Information for Readers","authors":"","doi":"10.1016/S0147-0272(25)00086-8","DOIUrl":"10.1016/S0147-0272(25)00086-8","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"59 ","pages":"Article 101259"},"PeriodicalIF":2.3,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145578610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号